• Investors
    • Our business units
    • Message from the Chairman
    • Oncodesign shares
    • Regulated Information [FR]
    • General meetings
    • Analysts coverage
    • Investor Day
    • Letters to our shareholders
    • Financial news
  • Careers
    • Oncodesign is recruiting!
    • HR-policy
    • Our employees
    • Professional Equality Index
  • Resources
    • Scientific resources
      • Webinar
      • Posters
      • Scientific publications
    • Press
      • Press release
      • Press coverage
      • Media kit
    • News
Oncodesign
linkedin twitter Stand with Ukraine
oncodesign_logotype_texte_et_baseline_blanc
Oncodesign
  • Service
    • EXPLORE: Identification and validation of therapeutic targets
    • DRIVE-IDDS: integrated drug discovery solution
      • DRIVE SM
      • DRIVE-MRT
    • SOLO: offers from our innovative technical platforms
      • SOLO – PoC Oncology
      • SOLO – PoC Immuno-inflammation
      • SOLO – PoC Covid-19
      • SOLO – Pharmaco-imaging
      • SOLO – DMPK- Bioanalysis
      • SOLO – Microbiome
    • INPACT: integrated service in preclinical pharmacology
    • D-VLOP: partners in preclinical and clinical development
  • Biotech
    • Nanocyclix® technology
    • Innovative kinase inhibitors platform
    • Chemical biology
    • R&D Portofolio
    • Partnership Nanocyclix®
    • Partnership Opportunities
  • Artificial intelligence
    • OncoSNIPER
    • Our internal databases
    • Our collaborations
    • Our commercial offers
  • Innovation technologies
    • OncoSNIPER : Discovering new targets
    • Nanocyclix® technology: novel and next generation kinase inhibitors
    • Pharmimage®: pharmaco-imaging module
    • Chi-mice® humanized models
    • PREDICT® to select the best drug candidates
    • T.O.T: Qualify the potential of your molecules
  • Homing program
  • About us
    • Our vision-mission
    • Our values
    • Our history
    • Our innovative model
    • Management
    • Our CSR approach
  • Contact us
  • Investors
    • Our business units
    • Message from the Chairman
    • Oncodesign shares
    • Regulated Information [FR]
    • General meetings
    • Analysts coverage
    • Investor Day
    • Letters to our shareholders
    • Financial news
  • Careers
    • Oncodesign is recruiting!
    • HR-policy
    • Our employees
    • Professional Equality Index
  • Resources
    • Scientific resources
      • Webinar
      • Posters
      • Scientific publications
    • Press
      • Press release
      • Press coverage
      • Media kit
    • News
  • Search

    More results...

    Generic filters
  • Drug Discovery Service

    Integrated or stand alone Drug Discovery services (from hit findings to IND), to discover & evaluate the therapies of tomorrow together. 

    Discover
    News

    [Webinar] How to better optimize an oncology drug discovery program

    Register for this webinar discussing how conventional and innovative integrated technological skills should be incorporated into an oncology program.
    Read more

    Participate in research and development programs

    Value creation through innovative technologies & R&D partnerships

    Discover
    News

    Parkinson’s Disease: Growing Prevalence And Continued Significant Medical Need

    Explore the disease & find out about our strategic R&D collaboration with Servier: info, press re
    Read more

    Artificial intelligence for therapeutic innovation

    For Oncodesign, artificial intelligence (AI) is a powerful tool for accelerating and making drug development more reliable.

    Discover how Oncodesign uses AI

    Our innovation technologies, a continuum from the molecule to the patient

    For more than 25 years, Oncodesign has been investing in precision medicine innovation technologies, which are essential from the very first stages of the Drug Discovery process.

    Discover

    Oncodesign, experts in precision medicine

    Oncodesign’s mission is to discover new innovative therapies that are effective against cancers and serious diseases with no known treatments.

    Discover

    Posts

    • Pages

      • 404
      • About us
        • Management
        • Our CSR approach
        • Our history
        • Our innovative model
        • Our values
        • Our vision-mission
      • Artificial intelligence
        • OncoSNIPER
        • Our collaborations
        • Our commercial offers
        • Our internal databases
      • Biotech
        • Chemical biology
        • Kinase inhibitors
        • Nanocyclix® technology
        • Partnership Nanocyclix®
        • Partnership Opportunities
        • R&D Portofolio
      • Careers
        • HR-policy
        • Job offers
          • Application form
        • Our employees
        • Professional Equality Index
      • Contact us
      • General Terms And Conditions Of Purchase
      • Hit identification
      • Homing program
      • In production
      • In vitro assay development
      • in vivo model
      • Innovation technologies
        • Chi-mice® humanized models
        • Nanocyclix® technology: optimization of therapeutic targets
        • OncoSNIPER : Discovering new targets
        • Pharmimage®: pharmaco-imaging module
        • PREDICT® to select the best drug candidates
        • T.O.T: Qualify the potential of your molecules
      • Integrated Drug Discovery Services
      • Investors
        • Analysts coverage
        • Financial news
        • General meetings
        • Investor Day
          • Investor Day 2018 (FR)
          • Investor Day 2019 (FR)
          • Investor Day 2020 (FR)
          • Investor day 2021 [FR]
        • Letters to our shareholders
        • Message from the Chairman
        • Oncodesign shares
        • Our business units
        • Regulated Information [FR]
      • Lead optimization of radiopharmaceuticals for molecular radiotherapy and preclinical evaluation  | #1401
      • Legal notice
      • Mouse models of hepatocellular carcinoma: a comprehensive & functional preclinical platform for immunotherapy research | #1654
      • News
      • Newsletter
      • Oncodesign, a pioneer in precision medicine
      • Personal data policy
      • Resources
      • Service
        • D-VLOP: partners in preclinical and clinical development
        • DRIVE-IDDS: integrated drug discovery solution
          • DRIVE SM
          • DRIVE-MRT
        • EXPLORE: Identification and validation of therapeutic targets
        • INPACT: integrated service in preclinical pharmacology
          • INPACT PoC Oncology
        • SOLO: offers from our innovative technical platforms
          • SOLO – DMPK- Bioanalysis
          • SOLO – Microbiome
          • SOLO – Pharmaco-imaging
          • SOLO – PoC Covid-19
          • SOLO – PoC Immuno-inflammation
          • SOLO – PoC Oncology
      • Structure based design of small macrocyclic CDK9 degraders as chemical biology tools and beyond | #1398
      • Using individual or a consortium of bacteria for immuno-oncology research | #3053
    • Archives

      • Categories

        • No categories

        Contact-us

        18 rue Jean Mazen - FR - 21000 Dijon
        Tel.+33 380 788 260

        Get in touch

        Science within easy reach!

        Receive our general letter or our financial news!

        Explore Oncodesign's vitality
        oncodesign_logotype_texte_et_baseline_blanc

        Follow us

        linkedin twitter Stand with Ukraine
        • Service
          • EXPLORE: Identification and validation of therapeutic targets
          • DRIVE-IDDS: integrated drug discovery solution
            • DRIVE SM
            • DRIVE-MRT
          • SOLO: offers from our innovative technical platforms
            • SOLO – PoC Oncology
            • SOLO – PoC Immuno-inflammation
            • SOLO – PoC Covid-19
            • SOLO – Pharmaco-imaging
            • SOLO – DMPK- Bioanalysis
            • SOLO – Microbiome
          • INPACT: integrated service in preclinical pharmacology
          • D-VLOP: partners in preclinical and clinical development
        • Biotech
          • Nanocyclix® technology
          • Innovative kinase inhibitors platform
          • Chemical biology
          • R&D Portofolio
          • Partnership Nanocyclix®
          • Partnership Opportunities
        • Artificial intelligence
          • OncoSNIPER
          • Our internal databases
          • Our collaborations
          • Our commercial offers
        • Innovation technologies
          • OncoSNIPER : Discovering new targets
          • Nanocyclix® technology: novel and next generation kinase inhibitors
          • Pharmimage®: pharmaco-imaging module
          • Chi-mice® humanized models
          • PREDICT® to select the best drug candidates
          • T.O.T: Qualify the potential of your molecules
        • Homing program
        • About us
          • Our vision-mission
          • Our values
          • Our history
          • Our innovative model
          • Management
          • Our CSR approach
        • Contact us
        • Investors
          • Our business units
          • Message from the Chairman
          • Oncodesign shares
          • Regulated Information [FR]
          • General meetings
          • Analysts coverage
          • Investor Day
          • Letters to our shareholders
          • Financial news
        • Careers
          • Oncodesign is recruiting!
          • HR-policy
          • Our employees
          • Professional Equality Index
        • Resources
          • Scientific resources
            • Webinar
            • Posters
            • Scientific publications
          • Press
            • Press release
            • Press coverage
            • Media kit
          • News
        • Legal notice
        • Personal data policy
        • General Terms And Conditions Of Purchase